<DOC>
	<DOCNO>NCT02507479</DOCNO>
	<brief_summary>The study hypotheses introduction dose escalate thiotepa , substitution busulfan melphalan , reduce toxicity allogeneic transplantation improve disease eradication patient lymphoid malignancy eligible standard transplantation .</brief_summary>
	<brief_title>Thiotepa-based Conditioning Allogeneic Stem-cell Transplantation ( SCT ) Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>1 . Age less physiologic 68 year . 2 . Patients MM , NHL , HL CLL indication allogeneic transplantation follow : 1 . MM ; patient relapse autologous transplant highrisk cytogenetic abnormality 2 . Aggressive lymphoma Hodgkin lymphoma ; relapse autologous transplant 3 . Follicular lymphoma ; failure least one prior regimen 4 . CLL ; failure prior therapy include Fludarabine combination 17p cytogenetic abnormality 3 . Patients must HLA match related unrelated donor willing donate either peripheral blood stem cell bone marrow . Matching base highresolution class I ( HLAA , B , C ) class II ( HLADRB1 , DQB ) typing . The goal transplant &gt; 3 x 106 CD34+ cell per kg body weight recipient 4 . Patients must sign write informed consent . 5 . Adequate birth control fertile patient . 1 . Bilirubin &gt; 3.0 mg/dl , transaminases &gt; 3 time upper normal limit 2 . Creatinine &gt; 2.0 mg/dl 3 . ECOGPerformance status &gt; 2 4 . Uncontrolled infection 5 . Pregnancy lactation 6 . Abnormal lung diffusion capacity ( DLCO &lt; 40 % predict ) 7 . Severe cardiovascular disease 8 . CNS disease involvement 9 . Pleural effusion ascites &gt; 1 liter 10 . Known hypersensitivity Fludarabine treosulfan 11 . Psychiatric conditions/disease impair ability give inform consent adequately cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>